` CHY (Chemometec A/S) vs DAX Index Comparison - Alpha Spread

CHY
vs
D
DAX Index

Over the past 12 months, CHY has underperformed DAX Index, delivering a return of -20% compared to the DAX Index's +12% growth.

Stocks Performance
CHY vs DAX Index

Loading
CHY
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CHY vs DAX Index

Loading
CHY
DAX Index
Difference
www.alphaspread.com

Performance By Year
CHY vs DAX Index

Loading
CHY
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Chemometec A/S vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Chemometec A/S
Glance View

Chemometec A/S, a Danish firm founded in the late 1990s, has carved a niche in the specialized world of biotech instrumentation. The company is renowned for developing and manufacturing high-precision cell counting and analysis instruments used predominantly in the life sciences sector. Its flagship product, the NucleoCounter®, has gained significant traction in laboratories and production facilities worldwide. This product stands out due to its accuracy and ease of use in counting various types of cells, whether in research or pharmaceutical production settings. Unlike traditional methods, Chemometec’s technology enables researchers to save time and reduce error, which is invaluable for laboratories looking to enhance their workflow efficiencies. Revenue for Chemometec is primarily generated through the sale of its advanced instruments and associated consumables, along with providing expert services that support the integration and maintenance of these technologies. The company's business model capitalizes on the growing global demand for sophisticated biomedical research tools, as innovation in the drug development and biotechnology sectors accelerates. By continuously investing in R&D, Chemometec not only ensures its products remain cutting-edge but also expands its applicability across new areas in the life sciences field. The strategy of maintaining close relationships with its end-users ensures that as the scientific landscape evolves, Chemometec is well-positioned to adapt and grow.

CHY Intrinsic Value
63 EUR
Undervaluation 3%
Intrinsic Value
Price
Back to Top